Physician profile
John M Cartwright
NPI 1841760733
$4,773.07
in general payments reported to CMS, 2019-2025
45 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,042 · 2022: $96.55 · 2024: $478 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $21.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.22 |
| Education | $21.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $961.07 | 2021-2025 | Wegovy, Ozempic, Sogroya |
| Corcept Therapeutics | $271.64 | 2021-2025 | Korlym |
| Lilly USA, LLC | $271.21 | 2021-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $238.61 | 2021 | |
| Amneal Pharmaceuticals LLC | $229.22 | 2021-2025 | Unithroid |
| Medtronic, INC. | $205.21 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $194.78 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $191.17 | 2021-2025 | Xyosted |
| Abbvie INC. | $185.88 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.12 | 2021-2025 | |
| Dexcom, INC. | $167.25 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $149.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.10 | 2021-2025 | Jardiance |
| Amgen INC. | $142.89 | 2021-2025 | Evenity, Prolia, Prolia |
| Merck Sharp & Dohme LLC | $118.59 | 2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.31 | 2021-2024 | |
| Madrigal Pharmaceuticals | $104.06 | 2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $90.95 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $81.32 | 2024-2025 | Crysvita |
| Cequr Corporation | $79.10 | 2021 | |
| Sequel Med Tech, LLC | $73.13 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $63.81 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $52.50 | 2024-2025 | Yorvipath, Skytrofa |
| Ibsa Pharma INC. | $46.90 | 2021 | |
| Alexion Pharmaceuticals, INC. | $44.64 | 2024 | Strensiq |
| Abbott Laboratories | $39.66 | 2025 | Freestyle Libre 3 |
| Radius Health, INC. | $34.18 | 2021-2022 | |
| Zealand Pharma US, INC. | $30.91 | 2021 | |
| Alvogen INC | $23.96 | 2025 | Teriparatide |
| Verity Pharmaceuticals INC. | $22.30 | 2025 | Tlando |
| Beta Bionics, INC. | $21.56 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Azurity Pharmaceuticals, INC. | $19.40 | 2025 | Triptodur |
| Tolmar, INC. | $16.96 | 2025 | Fensolvi |
| Recordati_rare_diseases_inc. | $16.72 | 2025 | Isturisa |
| Endo Pharmaceuticals INC. | $16.64 | 2021 | |
| Lifescan, INC. | $16.52 | 2021 | |
| Acella Pharmaceuticals, LLC | $16.51 | 2025 | NP Thyroid 60 |
| Sandoz INC. | $16.23 | 2025 | Omnitrope |
| Insulet Corporation | $14.94 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.17 | 2025 | |
| Pfizer INC. | $13.68 | 2021 | |
| Chiesi USA, INC. | $13.53 | 2025 | Mycapssa |
| Kowa Pharmaceuticals America, INC. | $11.96 | 2021 | |
| Organogenesis INC. | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.